drugset / Trial / NCT02489487

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

NCT02489487

Phase 1 Completed 24 enrolled Viriom
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach. The parallel design is used due to the long half life for VM-1500.

Timeline

Start
2014-09
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg
Subject Elsulfavirine Small molecule 40 mg Oral
Subject Raltegravir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified 100 mg